Results 101 to 110 of about 2,763 (183)

Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA. [PDF]

Pharmacoeconomics
Dong AW, Bounthavong M.
europepmc   +1 more source

Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis. [PDF]

Eur J Neurol
Garcés-Pellejero M, Torres-Ferrús M, Mas-de-Les-Valls R, Caronna E, Alpuente A, Giné-Ciprés E, Pozo-Rosich P.   +6 more
europepmc   +1 more source

Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience. [PDF]

Front Neurol
Gomaa MA, Taha NA, Helmy SM, Farag SM, Moustafa RR.   +4 more
europepmc   +1 more source

A multidisciplinary multicentric approach to the identification of predictive biomarkers of response to erenumab - the protocol of the phase 4, European, open-label controlled trial of the BIOMIGA project. [PDF]

Front Neurol
Martinelli D, Caronna E, Basedau H, Greco R, Pocora MM, Schönthaler M, De Icco R, Vaghi G, Sances G, Ghiotto N, Guaschino E, Allena M, Demartini C, Francavilla M, Pichiecchio A, Mas-de-Les-Valls R, Pareto D, Rovira À, Gallardo VJ, Asskour L, Gine-Cipres E, Alpuente A, Torres-Ferrús M, Ballante E, Castellazzi G, Mehnert J, May A, Pozo-Rosich P, Tassorelli C.   +28 more
europepmc   +1 more source

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants. [PDF]

Patient
Dias-Barbosa C, Igarashi H, Duenas A, Hareendran A, Kitamura S, Tanaka S, Sanno N, Doi H, Nagamitsu T, Tatsuoka Y, Matsumori Y, Hasebe M, Takeshima T.   +12 more
europepmc   +1 more source

Brain structural MRI changes before and after 6 months of preventive treatment with erenumab and onabotulinumtoxinA in migraine. [PDF]

J Headache Pain
Rosell-Mirmi J, Caronna E, Gallardo VJ, Pareto D, Alpuente A, Torres-Ferrús M, Giné-Ciprés E, Rovira À, Pozo-Rosich P.   +8 more
europepmc   +1 more source

Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study. [PDF]

J Ultrason
Barbella G, Antenucci P, Govoni V, Casetta I, Paciaroni M, Padroni M.   +5 more
europepmc   +1 more source

Anti-CGRP receptor antibodies do not modulate trigeminal pain processing: indication for distinct mechanisms of CGRP pathway blockade. [PDF]

J Headache Pain
Peng KP, Basedau H, Messlinger K, May A.
europepmc   +1 more source

Efficacy and safety of CGRP monoclonal antibodies in chronic migraine: a systematic review integrating randomized and real-world evidence. [PDF]

Neurol Sci
Carta D, Lo Buono V, Grugno R, Lo Presti R, Quartarone A, Marino S.   +5 more
europepmc   +1 more source

Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry-Based Real-World Study. [PDF]

Eur J Neurol
Lampl C, Suliman R, Tischler-Strasser V, MaassenVanDenBrink A, Alsaadi T.   +4 more
europepmc   +1 more source